Daniel Y Wang

发表

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

S. Mallal, J. Sosman, P. Gonzalez-Ericsson, 2019, Nature Medicine.

Correlates of response and outcomes with talimogene laherperpvec

Douglas B. Johnson, Fei Ye, K. Ancell, 2019, Journal of surgical oncology.

Clinical characterization of colitis arising from anti-PD-1 based therapy

R. Sullivan, J. Sosman, Douglas B. Johnson, 2018, Oncoimmunology.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Stephen M. Douglass, D. Schadendorf, B. Schilling, 2018, Clinical Cancer Research.

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

A. Giobbie-Hurder, R. Sullivan, Douglas B. Johnson, 2020, Journal for immunotherapy of cancer.

Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma

J. Sosman, Douglas B. Johnson, Shilin Zhao, 2019, Journal of immunotherapy.

Toxicities Associated With PD-1/PD-L1 Blockade

Douglas B. Johnson, E. Davis, Daniel Y Wang, 2018, Cancer journal.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy

R. Sullivan, Douglas B. Johnson, A. Shoushtari, 2018, Cancer.

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

J. McQuade, Douglas B. Johnson, G. Long, 2019, The oncologist.

Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients

Kevin B. Taylor, R. Sullivan, Douglas B. Johnson, 2019, Cancer Immunology Research.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

R. Sullivan, W. Rathmell, J. Sosman, 2018, JAMA oncology.

Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma

Ju-Seog Lee, Hee-Jin Jang, Hyun-Sung Lee, 2021, bioRxiv.

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis

A. Sabichi, B. Burt, F. Mott, 2019, Oncoimmunology.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

S. Loi, J. Kim, J. Sosman, 2018, JCI insight.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Matthew Wongchenko, Jeffrey E Gershenwald, Lauren E Haydu, 2018, The Lancet. Oncology.

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis

Douglas B. Johnson, Shilin Zhao, Fei Ye, 2017, Oncoimmunology.

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.

P. Ascierto, Douglas B. Johnson, G. Long, 2021, European journal of cancer.

Cardiovascular Toxicities Associated with Cancer Immunotherapies

Douglas B. Johnson, J. Moslehi, T. Neilan, 2017, Current Cardiology Reports.

Advances in the development of intralesional therapies for melanoma.

Douglas B. Johnson, Daniel Y Wang, 2016, Melanoma management.

Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma

J. Sosman, F. Hodi, Douglas B. Johnson, 2017, Cancer Immunology Research.

Rising Incidence of Colorectal Cancer Among Young Hispanics in Texas

A. Thrift, M. Bondy, P. Thompson, 2017, Journal of clinical gastroenterology.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

S. Mallal, J. Sosman, Douglas B. Johnson, 2019, Nature Medicine.

Update on immune therapy in melanoma

Douglas B. Johnson, Daniel Y Wang, 2016 .

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab

M. Abdelrahim, C. Yee, W. Glass, 2020, Journal for ImmunoTherapy of Cancer.

Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma.

Ju-Seog Lee, Hee-Jin Jang, Hyun-Sung Lee, 2021, Annals of Thoracic Surgery.

Molecular characterization of immune-related severe adverse events (irSAE).

J. Sosman, Douglas B. Johnson, J. Balko, 2017 .

When to consider alternatives to front-line immune therapies in metastatic melanoma.

Douglas B. Johnson, Daniel Y Wang, 2017, Melanoma management.

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease.

Douglas B. Johnson, K. Beckermann, Daniel Y Wang, 2018, Oncology.

Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma

Carlino, J. Sosman, J. McQuade, 2016 .

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

J. McQuade, Douglas B. Johnson, G. Long, 2020 .

Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.

Douglas B. Johnson, G. Gibney, I. Puzanov, 2017 .

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy.

R. Sullivan, Douglas B. Johnson, A. Shoushtari, 2018 .

Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.

J. McQuade, Douglas B. Johnson, R. Amaria, 2018 .

Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access

A. Sabichi, A. Jotwani, V. Sandulache, 2022, Cancer research communications.

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

P. Ascierto, Douglas B. Johnson, G. Long, 2018 .

Therapeutic targeting of macrophage plasticity remodels the tumor-immune microenvironment.

Ju-Seog Lee, S. Jung, Hee-Jin Jang, 2022, Cancer research.